A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
A. R. Townsend
No relevant relationships to disclose
L. Pirc
No relevant relationships to disclose
J. Hardingham
No relevant relationships to disclose
C. S. Karapetis
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Amgen (U)
N. Singhal
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Amgen (U)